Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

(S)-{8-fluoro-2-2[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)-phenyl]-3,4-dihydro-4-quinazolinyl} acetic acid

EU orphan designation number: EU/3/11/849   
Active ingredient: (S)-{8-fluoro-2-2[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)-phenyl]-3,4-dihydro-4-quinazolinyl} acetic acid
Indication: Prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity deemed at risk
Sponsor: Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name PREVYMIS on 08/01/2018 with the number EU/1/17/1245

   Public summary of scientific opinion     EPAR

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
19/04/2011 Orphan designation EMA/OD/090/10 (2011)2836 of 15/04/2011
19/03/2013 Transfer of orphan designation EMA/OD/090/10/T/01 (2013)1714 of 15/03/2013